Skip to main content
Kingchem (Liaoning) Life Science Co., Ltd. logo

Kingchem (Liaoning) Life Science Co., Ltd. — Investor Relations & Filings

Ticker · 301509 ISIN · CNE1000066M6 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2026-05-25 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 301509

About Kingchem (Liaoning) Life Science Co., Ltd.

https://www.kingchemchina.com

Kingchem (Liaoning) Life Science Co., Ltd. is a Contract Development and Manufacturing Organization (CDMO) specializing in the production of fine chemicals, advanced intermediates, and active pharmaceutical ingredients (APIs). The company provides comprehensive services across the product lifecycle, including custom synthesis, process research and development, scale-up, and large-scale commercial manufacturing. Serving the global pharmaceutical, agrochemical, and specialty chemical sectors, Kingchem utilizes advanced chemical technologies such as fluorination, hydrogenation, and organometallic chemistry. The facility operates under rigorous quality standards, including ISO certifications and cGMP compliance, ensuring high-quality outputs for international clients. Its technical expertise and integrated manufacturing capabilities enable the efficient delivery of complex chemical solutions tailored to specific customer requirements.

Recent filings

Filing Released Lang Actions
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 92% confidence The document is a public announcement by the company of its 2025 annual profit distribution (cash dividend) scheme, specifying the dividend per 10 shares, total amount, record date, ex-dividend date, distribution mechanism, and tax treatments. This directly matches the definition for Notice of Dividend Amount (DIV).
2026-05-25 Chinese
关于公司股东减持股份的预披露公告
Major Shareholding Notification Classification · 92% confidence The document is a shareholder pre-disclosure announcement detailing planned reductions of equity stakes by existing significant shareholders (investment funds) and their compliance with lock‐up and disclosure obligations. It is not the company repurchasing its own shares, nor is it a corporate finance or management change filing. It falls under notifications of changes in major share ownership levels. Therefore, it is classified as a Major Shareholding Notification (MRQ).
2026-05-22 Chinese
北京市中伦（青岛）律师事务所关于金凯（辽宁）生命科技股份有限公司2025年度股东会的法律意见书
Regulatory Filings Classification · 89% confidence The document is a legal opinion letter (“法律意见书”) issued by a law firm to attest to the legality of the 2025 annual shareholders’ meeting procedures, voting results, and related matters. It is not the meeting notice itself nor the full AGM materials (presentations or minutes), nor a financial report; rather it is a compliance/attestation document. Under the “CERTIFICATION RULE,” attestation or opinion letters should be classified as general regulatory filings (RNS).
2026-05-22 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is the official announcement of the shareholder meeting resolutions and detailed voting results for the 2025 Annual Shareholders’ Meeting, including vote counts for each proposal. It does not present full financial statements or serve as a proxy solicitation but specifically reports voting outcomes. This matches the Definition for Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-22 Chinese
中信建投证券股份有限公司关于金凯（辽宁）生命科技股份有限公司2025年度跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2025年度跟踪报告" (2025 Annual Tracking Report) issued by a sponsor (中信建投证券股份有限公司) regarding 金凯（辽宁）生命科技股份有限公司. It contains detailed oversight and supervisory activities related to the company's governance, fundraising, internal controls, and performance monitoring for the year 2025. The content includes review of company disclosures, supervision of fundraising, governance oversight, and reporting on company performance and risks. It is not a full annual report (10-K) or interim report (IR) with financial statements, but rather a sponsor's tracking report on the company's compliance and performance. This type of document is typically classified as a Regulatory Filing (RNS) because it is a regulatory disclosure related to sponsor oversight and compliance monitoring rather than a financial report or earnings release. The document length is about 3091 characters, which is relatively short and consistent with a regulatory filing rather than a full report. Therefore, the best classification is Regulatory Filings (RNS).
2026-05-08 Chinese
关于2025年度计提资产减值准备的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the company's asset impairment provisions for the fiscal year 2025. It details the accounting treatment of asset impairment and credit loss provisions, including specific amounts and their impact on profit. The document references compliance with accounting standards and includes audit confirmation by an accounting firm. The length is 2415 characters, which is relatively short but contains substantive financial data about impairment provisions and their impact on the financial results for the year 2025. This is not a full annual report but a specific audit-related financial disclosure about asset impairment. It is not a report publication announcement or a certification letter but a detailed disclosure of audit-related financial adjustments. Therefore, it fits best under Audit Report / Information (AR). FY 2025
2026-04-24 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.